Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors

Annals of Nuclear Medicine

Volumn 28, Issue 6, 2014, Pages 531-539

  Calais, Phillipe J ^a   Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Outpatient radionuclide therapy; Radiation exposure; Radiopeptide therapy

Indexed keywords

APREPITANT; DEXAMETHASONE; LORAZEPAM; LUTETIUM 177; LUTETIUM OCTREOTATE LU 177; TROPISETRON; UNCLASSIFIED DRUG; 177LU-OCTREOTATE; LUTETIUM; OCTREOTIDE; RADIOISOTOPE;

ADULT; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OUTPATIENT; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION SAFETY; WHOLE BODY RADIATION; ANALOGS AND DERIVATIVES; CANCER CENTER; CAREGIVER; COHORT ANALYSIS; ENVIRONMENTAL EXPOSURE; HEALTH CARE PERSONNEL; NEUROENDOCRINE TUMORS; OCCUPATIONAL EXPOSURE; RADIATION MONITORING; RADIOMETRY; URINE;

CANCER CARE FACILITIES; CAREGIVERS; COHORT STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; HEALTH PERSONNEL; HUMANS; LUTETIUM; MALE; NEUROENDOCRINE TUMORS; OCCUPATIONAL EXPOSURE; OCTREOTIDE; OUTPATIENTS; RADIATION MONITORING; RADIOISOTOPES; RADIOMETRY;

EID: 84904380987     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-014-0843-8     Document Type: Article

References (27)

1. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-30.
2. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125-35.
3. 177Lu][DOTA0, Tyr3]octreotate. Q J Nucl Med Mol Imaging. 2006;50:265-71.
4. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302-11.
5. 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27:561-9.
6. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220-6.
7. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102:1106-12.
8. Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012;42:190-207.
9. Turner JH. Outpatient therapeutic nuclear oncology. Ann Nucl Med. 2012;26:289-97.
10. ARPANSA. Radiation protection in the medical applications of ionizing radiation. Melbourne: ARPANSA; 2008.
11. ARPANSA. Safety guide for radiation protection in nuclear medicine. Melbourne: ARPANSA; 2008.
12. ARPANSA. Discharge of patients undergoing treatment with radioactive substances, RPS4. Melbourne: ARPANSA; 2002.
13. ICRP (2004) Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. Ann ICRP. 2004;34(2)
14. IAEA. Release of patients after therapy with unsealed radionuclides. Vienna: IAEA; 2004.
15. IAEA. Release of patients after radionuclide therapy. Vienna: IAEA; 2009.
16. De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2012;27:72-6.
17. 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788-97.
18. Government of Western Australia. Radiation safety (general) regulations 1983 schedule VIII (2008 amendment). Perth: State Law Publisher; 1983.
19. IAEA. International basic safety standards for protection against ionizing radiation and for the safety of radiation sources. Vienna: IAEA; 1996.
20. Hoefnagel CA, Clarke SE, Fischer M, Chatal JF, Lewington VJ, Nilsson S, et al. Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee. Eur J Nucl Med. 1999;26:277-82. (Pubitemid 29139860)
21. Kuyvenhoven JD, Busemann Sokole E, van Rijk P, Clausen M, Jamar F, Slegers G, et al. A survey of guidelines in 27 EANM associated societies by the EANM Task Group on Quality Assurance and Standardisation. European Association of Nuclear Medicine. Eur J Nucl Med. 2000;27:BP31-44.
22. 131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2012;26:99-112.
23. 131)I therapy. J Nucl Med. 2011;52:681-2.
24. 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335-46.
25. 131I-rituximab radioimmunotherapy for non-hodgkin lymphoma: a study in safety. Clin Nucl Med. 2012;37:732-7.
26. Calais PJ, Page AC, Turner JH. Management of fear of radiation exposure in carers of outpatients treated with iodine-131. Ann Nucl Med. 2012;26:508-14.
27. US Nuclear Regulatory Commission, Release of Patients Administered Radioactive Materials. Washington DC. US NRC 1997, Regulatory Guide 8.39.